|Year : 2015 | Volume
| Issue : 5 | Page : 560-562
Telmisartan induced urticarial vasculitis
Vikram K Mahajan1, Ravinder Singh1, Mrinal Gupta1, Rashmi Raina2
1 Department of Dermatology, Venereology and Leprosy, Dr. R. P. Government Medical College, Kangra (Tanda), Himachal Pradesh, India
2 Department of Pathology, Dr. R. P. Government Medical College, Kangra (Tanda), Himachal Pradesh, India
|Date of Submission||26-May-2015|
|Date of Decision||16-Jun-2015|
|Date of Acceptance||22-Aug-2015|
|Date of Web Publication||15-Sep-2015|
Dr. Vikram K Mahajan
Department of Dermatology, Venereology and Leprosy, Dr. R. P. Government Medical College, Kangra (Tanda), Himachal Pradesh
Source of Support: None, Conflict of Interest: None
A 53-year-old man developed urticarial vasculitis following ingestion of telmisartan and hydrochlorothiazide combination for hypertension. Treatment with prednisolone and cetirizine was curative, but his lesions recurred when he continued telmisartan and hydrochlorothiazide against medical advice. Re-challenge with the same doses of telmisartan precipitated similar lesions with telmisartan and not with hydrochlorothiazide. This uncommon cutaneous adverse reaction of angiotensin II receptor blockers has implication for the clinicians as more such cases may become apparent with their wider use than in premarketing studies.
Keywords: Angiotensin-converting-enzyme inhibitors, angiotensin II receptor blocker, ecchymosis, urticaria
|How to cite this article:|
Mahajan VK, Singh R, Gupta M, Raina R. Telmisartan induced urticarial vasculitis. Indian J Pharmacol 2015;47:560-2
| » Introduction|| |
Among several angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II receptor blocker (ARB) drugs, telmisartan + hydrochlorothiazide combination is a frequently prescribed antihypertensive in patients who do not achieve the desired effect after monotherapy. Henoch-Schönlein purpura, atypical lymphoid cutaneous infiltration, purpuric rash with vasculitis or acute nephritis, and polycyclic rash with systemic illness, and urticaria with or without angioedema are infrequently reported cutaneous adverse effects with ARBs. Similarly, phototoxic dermatitis, subacute cutaneous lupus erythematosus, erythema annulare centrifugum and acute eczematous dermatitis, and morbilliform and leukocytoclastic vasculitis may be induced by hydrochlorothiazides. There is also an instance of symmetrical drug-related intertriginous and flexural exanthema being attributed to this combination itself. Although losartan and candesartan from ARBs have been implicated for vasculitis, telmisartan is not a described cause of vasculitis. Here, we describe a case of urticarial vasculitis following ingestion of telmisartan, a commonly prescribed antihypertensive drug.
| » Case Report|| |
A 53-year-old man was hospitalized with deep dusky red lesions over trunk and extremities for 5 days. The lesions were persistent and had intense pruritus and burning. He was hypertensive and taking telmisartan + hydrochlorothiazide (40 + 12.5 mg/day) regularly for 2 weeks and infrequently for the past 16 months. He was afebrile and had no other systemic symptoms. Coalescing, dusky red and ecchymotic lesions of urticarial vasculitis having variable size and shape were widespread over abdomen, flanks, groins, buttocks, and extremities [Figure 1]. Hemogram showed mild leukocytosis (total leukocyte count - 12,800/cmm, normal - 4000–11000/cmm) and neutrophilia (N82%, L14%, E1%, M3%). C-reactive protein was positive. Other laboratory investigations, including serum biochemistry, throat swab culture, Widals test, antistreptolysin-O titer, serum cryoglobulins and complements (C3, C4), antibodies for hepatitis A, B, and C, antinuclear antibodies, rheumatoid factor, prostate-specific antigen, venereal disease research laboratory, human immunodeficiency virus (HIV) serology, G6PD estimation, chest X-rays, abdominal ultrasonography, and urinalysis, were normal. Skin biopsy showed unremarkable epidermis, mild dermal edema and perivascular inflammatory cell infiltrate comprising lymphohistiocytes, neutrophils, and occasional eosinophils in papillary and upper dermis, focal vascular endothelial swelling, and extravasation of erythrocytes suggestive of urticarial vasculitis [Figure 2]. With the possibility of drug-induced urticarial vasculitis, telmisartan + hydrochlorothiazide combination was switched with amlodipine 5 mg/day. He improved symptomatically after 10 days' treatment with cetirizine (10 mg/day) and prednisolone (40 mg/day). Blood counts were normalized and prednisolone was tapered off over next 3 weeks with advice to strictly avoid telmisartan + hydrochlorothiazide and continue amlodipine only. He was re-hospitalized for recurrence within a week after stopping prednisolone. He revealed that he had continued taking telmisartan + hydrochlorothiazide. The drugs were withdrawn immediately, and he was managed with systemic prednisolone as earlier. Two weeks after stopping prednisolone, with informed consent, a drug re-challenge test was performed as per previously described methodology. Briefly, he was administered a half dose of the hydrochlorothiazide under direct supervision on day 1 followed by full dose next day when it did not elicit any cutaneous rash. On day 3, he was administered telmisartan in a similar manner. Lesions of urticarial vasculitis of less intensity were elicited with 40 mg of telmisartan but not with 20 mg. He was advised to strictly avoid ARBs/ACE inhibitors in the future.
|Figure 1: Characteristic dusky, deep red to brown colored, coalescing, ecchymotic lesions over trunk, flanks, and gluteal region in the various stages of development. Note: Erythematous urticarial lesions (arrow in panel A), with central pallor (arrow in panel B)|
Click here to view
|Figure 2: (a) Histology shows unremarkable epidermis, mild dermal edema and perivascular inflammatory cell infiltrate in papillary and upper dermis, and hemosiderin deposition in epidermo-dermal areas (H and E, ×10). (b) Focal vascular endothelial swelling and cellular infiltrate comprised lymphohistiocytes, neutrophils and occasional eosinophils, and extravasation of erythrocytes (H and E, ×40)|
Click here to view
| » Discussion|| |
Urticarial vasculitis is an uncommon clinicopathological entity that may be hypo-complementemic (low C1q and C4 levels and variably decreased C3 levels), occurs almost exclusively in female patients, or normo-complementemic. Its reported prevalence is about 5–10% in chronic urticaria patients wherein episodes of urticaria are characteristically associated with leukocytoclastic vasculitis. However, lymphocyte-predominant cellular infiltrate with an admixture of eosinophils is observed more frequently than leukocytoclastic vasculitis. It remains idiopathic in most cases or is secondary to connective tissue diseases with a prevalence of 20% in systemic lupus erythematosus and 32% in Sjogren's syndrome. Serum sickness, neoplasia (leukemias or tumors of breast, pituitary, thyroid, colon, and pancreas), and infections (hepatitis B, hepatitis C, HIV, syphilis, and infectious mononucleosis) are commonly described causes. Clinically, wheals in urticarial vasculitis last for 48–72 h and angioedema involving lips, tongue, eyelids, and hands may occur additionally in 40% cases. The lesions differ from true urticaria in their association with burning, pain or tenderness, purpura, and induration that resolve usually with purpura or hyperpigmentation. Hypo-complementemic variety being severe form may be associated with fever, malaise, myalgia, fatigue, and organopathy (arthralgia, arthritis, serositis, glomerulonephritis, and interstitial nephritis), Raynaud's phenomenon or conjunctivitis, and episcleritis. Skin ulcers or multiorgan damage (lungs, eyes, and kidneys) is not uncommon in secondary or hypo-complementemic variety. Normo-complementemic or idiopathic cases usually respond to antihistamines or nonsteroidal anti-inflammatory drugs (NSAIDs) (ibuprofen and naproxen) while patients with organopathy or severe disease will require systemic corticosteroids or other disease modifying drugs (hydroxychloroquine, colchicine, dapsone, azathioprine, or cyclophosphamide). Although spontaneous resolution occurs usually in normo-complementemic or idiopathic cases, the overall prognosis depends upon the prognosis of the underlying cause.
Drugs have been implicated in about 10% of vasculitis cases and diltiazem, cimetidine, antibiotics, interferon, NSAIDs, and potassium iodide remain as commonly implicated drugs. Glatiramer, glimepiride, enalapril, and levetiracetam  too have been reported to elicit urticarial vasculitis. Curiously, the drugs appear to elicit urticarial vasculitis after a variable period irrespective of dose and frequency of drug administration. For instance, a 48-year-old female developed histologically confirmed urticarial vasculitis 3 months after glatiramer acetate administered for multiple sclerosis, glimepiride induced urticarial vasculitis in a 72-year-old woman occurred 6 weeks after starting the drug, and urticarial vasculitis appeared 8 days after enalapril therapy. Similarly, our patient developed urticarial vasculitis only recently despite ingesting the implicated antihypertensive infrequently during >1-year period. Apparently, he developed urticarial vasculitis only when he started taking the drug more frequently. However, the reasons for such a phenomenon remain unelucidated for now.
The diagnosis of drug-induced urticarial vasculitis in most cases is by exclusion of other known causes, temporal correlation between drug intake and onset of skin eruptions, clinicopathological correlation, and improvement of the symptoms after withdrawal of suspected drug (de-challenge), or re-challenge. The described patient was normo-complementemic, recovered after withdrawal of suspected antihypertensive, and re-challenge test imputed his lesions to telmisartan. The causality assessment by World Health Organization Uppsala Monitoring Centre causality scale was "certain" in view of temporal correlation to drug intake, complete clearance and no recurrence of skin lesions after drug withdrawal (de-challenge), and recurrence after re-challenge. Clinicians need to be aware of this uncommon cutaneous adverse reaction, as more cases may become apparent with the wider use of ARBs than in pre-marketing studies.
Financial Support and Sponsorship
Conflicts of Interest
There are no conflicts of interest.
| » References|| |
Bays H, Zhu D, Schumacher H. Single-pill combination of telmisartan and hydrochlorothiazide: Studies and pooled analyses of earlier hypertension treatment. High Blood Press Cardiovasc Prev 2014;21:119-26.
Ferreira O, Mota A, Morais P, Cunha AP, Azevedo F. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by telmisartan-hydrochlorothiazide. Cutan Ocul Toxicol 2010;29:293-5.
Ramam M, Kumar U, Bhat R, Sharma VK. Oral drug provocation test to generate a list of safe drugs: Experience with 100 patients. Indian J Dermatol Venereol Leprol 2012;78:595-8.
Her MY, Song JY, Kim DY. Hypocomplementemic urticarial vasculitis in systemic lupus erythematosus. J Korean Med Sci 2009;24:184-6.
Kulthanan K, Cheepsomsong M, Jiamton S. Urticarial vasculitis: Etiologies and clinical course. Asian Pac J Allergy Immunol 2009;27:95-102.
Cicek D, Kandi B, Oguz S, Cobanoglu B, Bulut S, Saral Y. An urticarial vasculitis case induced by glatiramer acetate. J Dermatolog Treat 2008;19:305-7.
Ben Salem C, Hmouda H, Bouraoui K. Glimepiride-induced vasculitis: A case report. Br J Clin Pharmacol 2007;64:113-4.
Koregol S, Naidu V, Rao S, Ankad BS. Enalapril induced normocomplementemic urticarial vasculitis. Indian J Dermatol Venereol Leprol 2015;81:73-4.
Mangal SS, Kumaran S. Levetiracetam induced urticarial vasculitis: A preliminary report. Indian J Dermatol 2014;59:423.
Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997;17:374-89.
[Figure 1], [Figure 2]
|This article has been cited by|
| ||Stephanie L. Gu, Joseph L. Jorizzo |
| ||International Journal of Women's Dermatology. 2021; 7(3): 290 |
|[Pubmed] | [DOI]|
||Belangrijk gewichtsverlies bij een patiėnt met een hardnekkige huideruptie
| ||E. VANBELLEGHEM, J. WERBROUCK, S. VERSTRAETE, L. LIBBRECHT, F. D'HEYGERE |
| ||Tijdschrift voor Geneeskunde. 2021; |
|[Pubmed] | [DOI]|
||Cutaneous effects of antihypertensive drugs
| ||Danilo Baccino, Giulia Merlo, Emanuele Cozzani, Gian M. Rosa, Giacomo Tini, Martina Burlando, Aurora Parodi |
| ||Giornale Italiano di Dermatologia e Venereologia. 2020; 155(2) |
|[Pubmed] | [DOI]|